RIPK1 and cancer: Nanomedicines can initiate a cascade leading to the rupture of cancer cell membranes and subsequent cell death by targeting specific receptors or signaling proteins involved in necroptosis, such as RIPK1 or RIPK3 (Fig. 3) [62].